144432-67-7

Basic information

• Product Name: 3,3-DIMETHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE
• Synonyms: 3,3-DIMETHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE
• CAS NO: 144432-67-7
• Molecular Formula: C₄H₁₀N₂O₂S
• Molecular Weight: 150.1994
• Mol File: 144432-67-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 223.8±23.0 °C(Predicted)
• Appearance: /
• Density: 1.194±0.06 g/cm3(Predicted)
• PKA: 12.77±0.40(Predicted)
• CAS DataBase Reference: 3,3-DIMETHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-DIMETHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE(144432-67-7)
• EPA Substance Registry System: 3,3-DIMETHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE(144432-67-7)

Safety Data

• Hazardous Substances Data: 144432-67-7(Hazardous Substances Data)

Upstream product

• 7803-58-9 SULFAMIDE 
• 811-93-8 1,1-dimethylethylenediamine 

Downstream Products

• 1193318-31-8 C₃₂H₃₅N₃O₅S₂ 
• 1092980-91-0 C₁₀H₁₂FN₃O₄S 

Relevant articles and documents

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

Novel lβ-methylcarbapenems having cyclic sulfonamide moieties: Synthesis and evaluation of in vitro antibacterial activity

The synthesis of a new series of 1β-methylcarbapenems having cyclic sulfonamide moieties is described. Their in vitro antibacterial activities against both Gram-positive and Gram-negative bacteria were tested and the effect of substituent on the pyrrolidi